Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Patten & Patten Inc. TN

Patten & Patten Inc. TN raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,494 shares of the company’s stock after buying an additional 671 shares during the period. Patten & Patten Inc. TN’s holdings in Moderna were worth $1,012,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Quadrant Capital Group LLC boosted its holdings in Moderna by 7.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after acquiring an additional 187 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Moderna by 6,528.9% in the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after purchasing an additional 381,808 shares in the last quarter. abrdn plc grew its holdings in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in Moderna during the 4th quarter worth approximately $1,358,000. Finally, Hobbs Group Advisors LLC acquired a new stake in Moderna during the 4th quarter worth approximately $664,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Moderna news, President Stephen Hoge sold 255 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the transaction, the president now owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the transaction, the president now directly owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $108.32, for a total transaction of $1,624,800.00. Following the sale, the director now owns 2,041,931 shares of the company’s stock, valued at $221,181,965.92. The disclosure for this sale can be found here. Insiders have sold 396,239 shares of company stock worth $55,286,137 over the last ninety days. 15.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MRNA. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Oppenheimer lifted their price objective on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, June 12th. Royal Bank of Canada boosted their price objective on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a research report on Monday, June 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $214.00 target price on shares of Moderna in a report on Thursday, June 27th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $134.02.

Moderna Price Performance

MRNA stock traded up $1.36 during trading on Monday, reaching $122.50. 1,787,408 shares of the company were exchanged, compared to its average volume of 4,062,705. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a market cap of $46.95 billion, a P/E ratio of -7.73 and a beta of 1.66. The stock’s 50 day moving average price is $135.45 and its 200 day moving average price is $114.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm’s revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 EPS. As a group, analysts predict that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.